Veritas Research ReportI am reading a research report by Veritas on CXR by the only analyst who was recommending to sell Valeant a year ago. This guy knows a thing or two about Valeant and pharma and from what I am reading he sees some of the same issues, only worse, with CXR. He has $27 price target on CXR.
Has anyone else read this? I am not an analyst and typically just use price to earnings, so am not too familiar with discounted cash flows he uses. I am hoping that maybe his numbers are off, but I think he has more experience than other analysts. The fact he saw the Valeant fiasco coming a year before anyone else, even the shorts, makes me think he might be onto something.
I like this company and stock, but I have to say, this report is making me very nervous going into earnings.
Roger